Edgewise director granted 16,377 stock options

Edgewise Therapeutics director Laura Brege received a new stock option grant covering 16,377 shares of common stock.

Rhea-AI Filing Summary

Edgewise Therapeutics director Laura Brege received a new stock option grant covering 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036. According to the grant terms, 100% of the options vest on the earlier of June 5, 2027 or the business day before the 2027 annual meeting of stockholders.

After this grant, Brege holds 16,377 stock options directly, all tied to this award.

Insider Trade Summary

Grant/Award: 16,377 shares

Grant/Award 1 txn

Insider Brege Laura

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,377	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,377 contracts (Direct)

Footnotes (1)

1. F1. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Key Figures

Option grant size: 16,377 shares Exercise price: $35.59 per share Expiration date: June 5, 2036 +2 more

5 metrics

Option grant size 16,377 shares Stock Option (Right to Buy) granted June 5, 2026

Exercise price $35.59 per share Exercise price for the stock option grant

Expiration date June 5, 2036 Option expiration date

Vesting date trigger June 5, 2027 Earlier of this date or business day before 2027 annual meeting

Options held after grant 16,377 options Total stock options following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, vested, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 35.5900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"100% of the Stock Options granted on June 5, 2026 will become vested"

expiration date financial

"expiration_date: 2036-06-05T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Edgewise Therapeutics (EWTX) director Laura Brege report in this Form 4?

Laura Brege reported receiving a stock option grant for 16,377 shares of Edgewise Therapeutics common stock. The options were granted as compensation, have a set exercise price, and will vest in full based on a specified future date or the 2027 annual meeting timing.

How many Edgewise Therapeutics shares are covered by Laura Brege’s new options?

The option award covers 16,377 shares of Edgewise Therapeutics common stock. This entire amount is tied to a single grant and represents Brege’s total stock option holdings following this transaction, as disclosed in the Form 4 insider filing.

What is the exercise price of Laura Brege’s Edgewise Therapeutics stock options?

The stock options granted to Laura Brege have an exercise price of $35.59 per share. This is the fixed price at which she may purchase Edgewise Therapeutics common stock once the options vest and become exercisable under the award terms.

When do Laura Brege’s Edgewise Therapeutics options vest?

All of the options vest 100% on the earlier of June 5, 2027, or the business day before Edgewise Therapeutics’ 2027 annual meeting of stockholders. This single vesting date governs the entire 16,377-share option grant reported in the filing.

When do Laura Brege’s Edgewise Therapeutics stock options expire?

The options granted to Laura Brege expire on June 5, 2036. After that expiration date, any unexercised portion of the 16,377-share option award will no longer be exercisable, according to the terms disclosed in the Form 4 filing.

Is this Edgewise Therapeutics Form 4 a market purchase or sale of shares?

No, this Form 4 reports a grant of stock options, not an open-market purchase or sale. It reflects a compensation-related award giving Laura Brege the right to buy Edgewise Therapeutics shares at $35.59 in the future, subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 05:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brege Laura

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.59	06/05/2026		A		16,377		06/02/2027(1)	06/05/2036	Common Stock	16,377	$0.00	16,377	D

Explanation of Responses:

1. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Remarks:

	/s/John R. Moore Attorney-in-Fact for Laura A. Brege	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)